Commentary - Archives of Pharmacology and Therapeutics (2021) Volume 3, Issue 1
The Use of Hydroxychloroquine and Interferons for the Prophylaxis of COVID-19
Catherine Teng1, Moses Shrestha2, Bing Yang2*
1Department of Internal Medicine, Yale New Haven Health Greenwich Hospital, Greenwich, CT 06830, USA
2Department of Biology, Saginaw Valley State University, University Center, MI 48710, USA
- *Corresponding Author:
- Bing Yang
Received date: November 03, 2020; Accepted date: January 20, 2021
Citation: Teng C, Shrestha M, Yang B. The Use of Hydroxychloroquine and Interferons for the Prophylaxis of COVID-19. Arch Pharmacol
Ther. 2021; 3(1):1-4.
Copyright: © 2021 Teng C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
At the beginning of Covid-19 pandemic, we proposed to use hydroxychloroquine (HCQ) and intranasal interferon (IFN) a-2b spray
to prevent SARS-CoV-2. Since then, clinical trials testing these two drugs separately for the treatment and prophylaxis have been
reported. A consensus is forming that HCQ and IFNs are not effective in treating severe Covid-19. However, the pathogenesis of
Covid-19 suggests that early intervention could reduce the infection and prevent the progression from mild to severe Covid-19. This
commentary will focus on discussion regarding the prophylaxis and early treatment of SARS-CoV-2 infection. After review and reanalysis
of the two randomized clinical trials (RCTs) using HCQ for postexposure prophylaxis, we concluded that HCQ is beneficial
for the prophylaxis of SARS-CoV-2. The side effects of HCQ are mild, and severe side effects such as life-threatening arrhythmia
are rare. Thus, risk-benefit ratio strongly suggests that the use of HCQ for pre-exposure prophylaxis should be available, especially
among high risk population with no known cardiovascular diseases. The risk-benefit ratio for postexposure prophylaxis is even better
for Covid-19 with a medium infection fatality rate of 0.27%. Clinical trials using type I IFN (IFN I) for prophylaxis are still ongoing.
Clinical studies using IFN Is for early or in mild Covid-19 hospitalized patients suggest that IFN a-2b may be beneficial. Clinical
trials testing the combination of HCQ and IFN Is in the prophylaxis and early treatment of SARS-CoV-2 are still needed to test if the
combination improves monotherapy treatment.
Covid-19, Hydroxychloroquine, Interferon, Prophylaxis
List of Abbreviations
COVID-19: Coronavirus disease 2019; HCQ: Hydroxychloroquine; IFN: Interferon; SARSCoV- 2: Severe Acute Respiratory Syndrome Coronavirus 2; RCTs: Randomized Controlled Trials; IU: International Unit; TMPSS2: Transmembrane Serine Protease 2; FDA: Food and Drug Administration; EKG: Electrocardiograph; QTc: QT corrected; IL-1: Interleukin-1; IL-6: Interleukin-6; TNF-α: Tumor Necrosis Factor alpha
Prophylactic pharmacological intervention has been largely focused on vaccination development. Until a vaccine is available, it is worth considering chemoprevention with data from clinical studies given the urgent need for interventions in a pandemic. Previously, we proposed to use a low dose of hydroxychloroquine (HCQ), 50 – 100 mg daily orally and intranasal IFN α-2b spray, 0.5 X 106 IU twice daily, for the prophylaxis of COVID-19 and recommended using an RCT to prove the efficacy and safety of combined use of HCQ and intranasal IFN α-2b spray . Although there are several clinical trials testing
existing drugs for COVID-19 prophylaxis, there has not been an RCT designed to test the efficacy and safety of
HCQ with intranasal IFN α-2b. Recent clinical evidence
suggests the efficacy of both HCQ in prophylaxis and IFN
in the early treatment of Covid-19. In this article, we will
review the clinical advances for the use of HCQ and IFN
in the prophylaxis and early treatment of Covid-19. More
importantly, the potential side effect of HCQ will be
reviewed after an extensive search of the available literature.
SARS-CoV-2 enters host cells by endocytosis via endosomal cleavage through protease cathepsin B/L and plasma membrane protease TMPSS2 cleavage . HCQ was shown to inhibit endocytosis process in vitro without
affecting TMPSS2 cleavage perhaps explaining the mixed
results with treatment of severe Covid-19 in hospitalized
patients. However, in postexposure prophylaxis, we
reviewed and re-analyzed the data from two RCTs showing
beneficial effect of HCQ compared to placebo. In the clinical
trial by Boulware et al., use of HCQ reduces the infection
rate in a time-dependent manner . Cochran-Amitage
analysis of trend indicates that the trend is statistically
significant (P=0.0496) . Even among infected patients
taking HCQ, the clinical trial by Mitja et al. suggested that
there are 55% more patients with antibody against SARSCoV-
2 on day 14 after the exposure compared to placebo
group. Presumably, these patients with earlier activation
of adaptive immune response will have better disease
outcome . Yang et al. have reviewed all the clinical
studies on the use of HCQ and IFN I . In the review,
there is a table listing all the important studies. Recently,
Rajasingham et al. reported another double-blinded RCT
enrolled 1483 healthcare workers using HCQ in preexposure
prophylaxis . They planned to recruit 3150
participants, however, due to the negative warning from
FDA, they could not reach the planned recruitment thus
decided to terminate the study early. They tested 400 mg
HCQ once weekly or twice weekly for participants against
placebo. The hazardous ratio for participants taking HCQ
once weekly is 0.72 and 0.74 for twice weekly; both were
insignificant. Overall incidence rate in HCQ group was
5.9% while the incidence rate in placebo group was 7.9%.
Since the incidence rate is low, the trial may not have
enough power to detect the efficacy of HCQ. It should also
be noted that HCQ used in postexposure prophylaxis study
carried out by Boulware et al. used much higher dosage.
HCQ or placebo was provided to the participants at 800
mg once, followed by 600 mg in 6 to 8 hours, then 600 mg
daily for 4 additional days. Risch and Hernan conducted
a meta-analysis of the available RCTs and concluded that
HCQ provided a significant 22-24% reduction in infection,
hospitalization, and death .
IFN I is able to inhibit viral replication and induce adaptive immune response. Delayed activation of IFN I response has been indicated in progression of mild to severe form of Covid-19 . In severe form of Covid-19, over 10% of the patients have autoantibodies against IFN I . Exogenous IFN I prior to viral entry shows promise in protecting against SARS-CoV-1 . We have recently reviewed the potential use of IFN I in the prophylaxis and early treatment [4,10]. From the studies of using IFN I in mild Covid-19 and from the pathogenesis of Covid-19, IFN I has potential against Covid-19. More recently, in an observational study, Wang et al. found that subcutaneous injection of IFN α-2b shortened the hospitalization stay and accelerated the viral clearance . Like HCQ, IFN α-2b effect on pathogenesis of Covid-19 seems to be timedependent; the earlier the use the more efficacious IFN α-2b is . However, in the SOLIDARITY study, IFN-β
was not found to be efficacious in hospitalized patients
. These conflicting results may be due to the differences in the time of use and the severity of Covid-19. Compared to SARS-CoV-1, SARS-CoV-2 was found to be much more sensitive to IFN-α in vitro . A later in vitro study
showed that IFN-β is more efficacious than INF-α .
This has prompted further study for the efficacy of using
IFN as part of regimen for prophylaxis and treatment of
COVID-19. There are currently 99 clinical trials using
IFN for Covid-19 registered on clinicaltrial.gov, and more
clinical data should be available soon. HCQ and IFN I
inhibit the viral replication through different mechanisms.
Combination of both drugs may have additive or synergetic
effect in inhibiting viral replication. Past success in
treatment of human immunodeficiency virus, hepatitis C
virus and hepatitis B virus also suggests that combination
therapy has higher chance of success.
The side effects of IFN α and β are well understood and manageable. When given intravenously, they are known to have significant side effects such as fever, myalgia, headache, fatigue, and gastrointestinal symptoms. Since inhaled IFN does not enter systemic circulation, only mild side effects such as nose bleed have been noted [15,16]. One study by Halme showed that except for slight elevated temperature and an 18% decrease in expiratory peak flow in one patient, all other patients did not experience any major side effects when treated with inhaled IFN β .
The debate concerned the side effects of HCQ is cited widely since the suggested use in Covid-19. HCQ was widely tolerated for malarial prophylaxis and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. EKG monitoring was not a standard of care for those patients to be treated by HCQ pre-COVID. Therefore, we conducted careful literature review on this subject. We found that HCQ is well tolerated with <10% reporting side effects, most of whom reported noncardiac symptoms . Though rare, a concerning potential side effect was QTc prolongation, which can cause lifethreatening arrhythmia. However, prior and current studies found that life-threatening arrhythmia is rarely seen in healthy, and in COVID-19 population. Lofgren et al. conducted three randomized, double-blind trials using HCQ as pre-exposure, post-exposure and early treatment for COVID-19 . 2,795 participants were enrolled; two individuals were hospitalized with atrial arrhythmias, one on placebo and one on HCQ. No sudden death was observed in both cohorts. The most common side effect reported was nausea and diarrhea . In a meta-analysis of a total of 177 clinical trials and 35,448 participants who received quinoline, 18,436 participants underwent evaluation. There has been no report of death or syncope attributable to cardiovascular causes including Torsade de Pointes . In a retrospective study of 201 hospitalized COVID-19 patients on HCQ, 59% of which also received
azithromycin (an agent that was known to prolong QTc),
though QTc prolongation was reported in HCQ group,
no instance of life-threatening arrhythmia was reported
. In recent clinical studies, the side effects from HCQ
were reported to be more common than the placebo
group, but no severe adverse reactions were noted [3,5].
In Mitja’s study, the most frequent treatment-related
adverse reactions were gastrointestinal (diarrhea, nausea,
and abdominal pain) and nervous system (drowsiness,
headache, metallic taste), and only 5 out of 1197 patients
experienced a cardiac side effect (palpitation) .
In patients with COVID-19 pneumonitis, some confounding factors may also contribute to QTc prolongation as well. For example, cytokine storm with elevated IL-1, IL-6, TNF-α in COVID patients may prolong the action potential and QTc interval . Low oxygen saturation was noted to be associated with prolonged QTc in human  and mice  model as well. Decreased tissue perfusion and cell oxygenation can cause aberrant gap junction phosphorylation, and misexpression of iron channels in cardiac tissue, which in turn prolongs QTc interval on electrocardiogram . It is thus likely that QT prolongation observed in hospitalized patient may be due to the additive effect of the symptoms from the late stage of Covid-19 and the use of HCQ.
Given the evidence, it is reasonable to conclude that HCQ is a relatively safe medication to be prescribed. In addition, though rare, given the clinically dismal outcome of arrhythmia, the American College of Cardiology has published detailed guidelines with instructions on inpatient and outpatient use and monitoring patients with a high risk for arrhythmia , but overall, HCQ poses as
a low cost and well-tolerated medication.
Currently, mask has been practiced in society as an effective measure to prevent the spread of the virus. Use of drugs for prevention along with mask wearing could help contain the spread of the virus.
Vaccine is always the first choice for infectious diseases. Prior to the availability of a vaccine of Covid-19, protecting the healthy population is still of paramount importance. Given the available evidence and careful consideration of risks and benefits of medication, we strongly suggest that HCQ be available for the pre-exposure prophylaxis of Covid-19 for patients with no known cardiovascular diseases at the discretion of primary physician and patients. The risk and benefit profile is even better for post-exposure prophylaxis thus the use of HCQ should become a general practice. We continue to propose conducting clinical trials to verify the efficacy of the dual use of HCQ and intranasal IFN I spray as prophylaxis and early treatment for patients with no known cardiovascular diseases, especially for high risk patients with no known cardiovascular diseases.
We thank Alexander Yang for his reading the manuscript
and for his correction of English expression.
Conflict of Interests
The authors have no actual or potential conflict of interest
with this study.
- Yang A, Yang C, Yang B. Use of hydroxychloroquine
and interferon alpha-2b for the prophylaxis of COVID-19.
Med Hypotheses. 2020;144:109802.
- Hoffmann M, Kleine-Weber H, Schroeder S,
Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2
Cell Entry Depends on ACE2 and TMPRSS2 and Is
Blocked by a Clinically Proven Protease Inhibitor. Cell.
- Boulware DR, Pullen MF, Bangdiwala AS, Pastick
KA, Lofgren SM, Okafor EC, et al. A Randomized Trial
of Hydroxychloroquine as Postexposure Prophylaxis for
Covid-19. N Engl J Med. 2020;383(6):517-25.
- Yang A, Liu Y, Shao Y, Yang CZ, Xu J, Yang B.
Hydroxychloroquine and Interferons for the Prophylaxis
and Early Treatment of Covid-19-Current Clinical
Advances. Journal of Clinical and Cellular Immunology.
- Mitja O, Ubals M, Corbacho-Monné M, Alemany
A, Suñer C, Tebe C, et al. A Cluster-Randomized Trial
of Hydroxychloroquine as Prevention of Covid-19
Transmission and Disease. MedRxiv. 2020.
- Rajasingham R, Bangdiwala AS, Nicol MR, Skipper
CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine
as pre-exposure prophylaxis for COVID-19 in healthcare
workers: a randomized trial. Clin Infect Dis. 2020.
- Ladapo AJ, McKinnon EJ, McCullough AP, Risch
H. Randomized Controlled Trials of Early Ambulatory
Hydroxychloroquine in the Prevention of COVID-19
Infection, Hospitalization, and Death: Meta-Analysis.
- Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao
J, Meyerholz DK, et al. Dysregulated Type I Interferon
and Inflammatory Monocyte-Macrophage Responses
Cause Lethal Pneumonia in SARS-CoV-Infected Mice.
Cell Host Microbe. 2016;19(2):181-93.
- Bastard P, Rosen LB, Zhang Q, Michailidis E,
Hoffmann HH, Zhang Y, et al. Autoantibodies against
type I IFNs in patients with life-threatening COVID-19.
- Yang A, Guduguntla SL, Yang B. Potential of
Interferons and Hydroxychloroquine for the Prophylaxis
and Early Treatment of COVID-19. Journal of Cellular
- Wang B, Li D, Liu T, Wang H, Luo F, Liu Y.
Subcutaneous injection of IFN alpha-2b for COVID-19:
an observational study. BMC Infect Dis. 2020;20(1):723.
- Rahmani H, Davoudi-Monfared E, Nourian A, Khalili
H, Hajizadeh N, Jalalabadi NZ, et al. Interferon beta-1b
in treatment of severe COVID-19: A randomized clinical
trial. Int Immunopharmacol. 2020;88:106903.
- Lokugamage KG. SARS-CoV-2 is sensitive to type I interferon pretreatment. 2020.
- Mantlo E, Bukreyeva N, Maruyama J, Paessler S,
Huang C. Antiviral activities of type I interferons to SARSCoV-
2 infection. Antiviral Res. 2020 Jul;179:104811.
- Turner RB, Felton A, Kosak K, Kelsey DK,
Meschievitz CK. Prevention of experimental coronavirus
colds with intranasal alpha-2b interferon. J Infect Dis.
- Higgins PG, Phillpotts RJ, Scott GM, Wallace J,
Bernhardt LL, Tyrrell DA. Intranasal interferon as
protection against experimental respiratory coronavirus
infection in volunteers. Antimicrob Agents Chemother.
- Halme M, Maasilta P, Mattson K, Cantell K.
Pharmacokinetics and toxicity of inhaled human natural
interferon-beta in patients with lung cancer. Respiration.
- Wozniacka A, Cygankiewicz I, Chudzik M, Sysa-
Jedrzejowska A, Wranicz JK. The cardiac safety of chloroquine phosphate treatment in patients with
systemic lupus erythematosus: the influence on
arrhythmia, heart rate variability and repolarization
parameters. Lupus. 2006;15(8):521-5.
- Lofgren S, Nicol MR, Bangdiwala AS, Pastick KA,
Okafor EC, Skipper CP, et al. Safety of Hydroxychloroquine
among Outpatient Clinical Trial Participants for
COVID-19. medRxiv. 2020.
- Haeusler IL, Chan XHS, Guerin PJ, White NJ.
The arrhythmogenic cardiotoxicity of the quinoline and
stucturally related antimalarial drugs: a systematic
review. BMC Med. 2018;16(1):200.
- Saleh M, Gabriels J, Chang D, Soo Kim B,
Mansoor A, Mahmood E, et al. Effect of Chloroquine,
Hydroxychloroquine, and Azithromycin on the Corrected
QT Interval in Patients With SARS-CoV-2 Infection. Circ
Arrhythm Electrophysiol. 2020;13(6):e008662.
- Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19,
Arrhythmic Risk, and Inflammation: Mind the Gap!
- Sievi NA, Clarenbach CF, Camen G, Rossi VA, van
Gestel AJ, Kohler M. High prevalence of altered cardiac
repolarization in patients with COPD. BMC Pulm Med.
- Morand J, Arnaud C, Pepin JL, Godin-Ribuot D.
Chronic intermittent hypoxia promotes myocardial
ischemia-related ventricular arrhythmias and sudden
cardiac death. Sci Rep. 2018;8(1):2997.
- Neary MT, Mohun TJ, Breckenridge RA. A mouse
model to study the link between hypoxia, long QT interval
and sudden infant death syndrome. Dis Model Mech.
- Simpson FT, Kovacs JR, Stecker CE. Ventricular
Arrhythmia Risk Due to Hydroxychloroquine-
Azithromycin Treatment for COVID-19. Cardiology